Theme
Gene editing
CRISPR and base/prime editing therapeutics.
Gene editing tools rewrite DNA directly to correct the underlying drivers of disease rather than manage symptoms. The field spans CRISPR nucleases alongside more precise base and prime editing approaches advancing toward durable, one-time treatments.
Companies · 4
Vertex Pharmaceuticals IncorporatedVRTX
Market cap$114B
Conviction5 / 5
Gene editing
Read profileCRISPR Therapeutics AGCRSP
Market cap$5.4B
Conviction4 / 5
Gene editing
Read profileBeam Therapeutics Inc.BEAM
Market cap$3.4B
Conviction3 / 5
Gene editing
Read profileIntellia Therapeutics, Inc.NTLA
Market cap$2.0B
Conviction3 / 5
Gene editing
Read profile